Charles Thomas
Optometrist · Amite, LANPI 1497715619
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 212 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. Among optometrist clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 212 payments — averaging $29.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Oyster Point Pharma, Inc.$856
- Bausch & Lomb Americas Inc.$672
- Alcon$505
- Sun Pharmaceutical Industries Inc.$394
- Bausch & Lomb, A Division Of Bausch Health US, LLC$351
- plus $2K from 16 others
What the payments were for
- Food & beverage$6,334100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 64 | $1,213 |
| Oyster Point Pharma, Inc. | 28 | $856 |
| Bausch & Lomb Americas Inc. | 24 | $672 |
| Alcon | 26 | $505 |
| Sun Pharmaceutical Industries Inc. | 9 | $394 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $351 |
| Glaukos Corporation | 2 | $284 |
| Optos, Inc. | 2 | $260 |
| Harrow Eye, LLC | 6 | $260 |
| Dompe US, Inc. | 6 | $252 |
| Novartis | 8 | $236 |
| Eyevance Pharmaceuticals LLC | 6 | $202 |
| Aerie Pharmaceuticals, Inc. | 9 | $191 |
| Rxsight Inc | 1 | $136 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $118 |
| Kala Pharmaceuticals, Inc. | 1 | $88 |
| LKC Technologies, Inc. | 1 | $80 |
| Tarsus Pharmaceuticals, Inc. | 4 | $76 |
| Shire North American Group Inc | 1 | $66 |
| Apellis Pharmaceuticals, Inc. | 1 | $52 |
| Astellas Pharma US Inc | 1 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFUSE$248
- PANORAMIC OPHTHALMOSCOPE$242
- Tecnis Simplicity$235
- CEQUA$208
- KXL System$146
- Photrexa$146
- P200DTx$139
- P200T$139
- P200TE$139
- P200TxE$139
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$136
- VUITY$126
- VEVYE$125
- OCT OPHTHALMOSCOPE$121
- NFC-700$121
- Tecnis IOL$118
- VERITAS Vision System$118
- ULTRA MULTIFOCAL TORIC$117
- Tobradex ST$112
- BIOTRUE$112
How this compares
$6,334 in reported general payments places this provider in the 90th percentile of 500 optometrist providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 324 | $115,851 |
| RestasisCyclosporine | 141 | $102,064 |
| RocklatanNetarsudil Mesylat/Latanoprost | 148 | $59,272 |
| VyzultaLatanoprostene Bunod | 179 | $58,333 |
| CombiganBrimonidine Tartrate/Timolol | 99 | $31,617 |
| XiidraLifitegrast | 41 | $31,350 |
| TyrvayaVarenicline Tartrate | 37 | $26,922 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 81 | $17,679 |
| RhopressaNetarsudil Mesylate | 45 | $17,632 |
| CequaCyclosporine | 16 | $14,531 |
| Alphagan PBrimonidine Tartrate | 49 | $13,013 |
| Latanoprost | 1,288 | $12,007 |
| VevyeCyclosporine | 12 | $10,508 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 697 | $9,303 |
| Fluorometholone | 131 | $8,563 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $1,213 | $262,545613 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $672 | $89,683220 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $191 | $76,904193 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $856 | $26,92237 claims |
| AlconSimbrinza | $505 | $17,67981 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $394 | $14,53116 claims |
| Harrow Eye, LLCVevye | $260 | $10,50812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 500 optometrist providers in Louisiana.
Other optometrist in Amite
- Christopher ThomasAmite$7K
- Pamela TheriotShreveport$207K
- Joshua DavidsonGonzales$189K
- Jeffrey WilhiteMarrero$86K
- Christopher WrotenHammond$59K
- James LamarNew Orleans$45K
- John McCallLogansport$32K
- Robert KellyMarrero$26K
- Shane FontenotJennings$23K
- Stephen LewisShreveport$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.